**6. References**


<sup>\*</sup> Corresponding Author


increasing ApoE mRNA in the translating pool via the estrogen receptor alphamediated pathway. J. Biol. Chem. 272: 33360-33366.

[23] Ciocca, D. R., and L. M. Roig (1995) Estrogen receptors in human nontarget tissues: biological and clinical implications. Endocr. Rev. 16: 35-62.

264 Lipoproteins – Role in Health and Diseases

11.

Semin. Oncol. 38: 431-438.

Pharmacol. Biochem. Behav. 85: 66-75.

management. Drugs 63: 1549-1563.

N. Y. Acad. Sci. 1019: 564-567.

12: 612-619.

[7] Struble, R. G., C. Cady, B. P. Nathan, and M. McAsey (2008) Apolipoprotein E may be a critical factor in hormone therapy neuroprotection. Front. Biosci. 13: 5387-5405. [8] Berteau-Pavy, F., B. Park, and J. Raber (2007) Effects of sex and APOE epsilon4 on object

[9] Mahley, R. W., and Y. Huang (2006) Apolipoprotein (apo) E4 and Alzheimer's disease: unique conformational and biophysical properties of apoE4 can modulate

[10] Chen, Y. C., G. Pohl, T. L. Wang, P. J. Morin, B. Risberg, G. B. Kristensen, A. Yu, B. Davidson, and M. Shih Ie (2005) Apolipoprotein E is required for cell proliferation and

[11] Ahles, T. A., and A. Saykin (2001) Cognitive effects of standard-dose chemotherapy in

[12] Meyers, C. A. (2008) How chemotherapy damages the central nervous system. J. Biol. 7:

[13] Janelsins, M. C., S. Kohli, S. G. Mohile, K. Usuki, T. A. Ahles, and G. R. Morrow (2011) An update on cancer- and chemotherapy-related cognitive dysfunction: current status.

[14] Nelson, C. J., N. Nandy, and A. J. Roth (2007) Chemotherapy and cognitive deficits: mechanisms, findings, and potential interventions. Palliat. Support. Care 5: 273-280. [15] Seigers, R., S. B. Schagen, C. M. Coppens, P. J. van der Most, F. S. van Dam, J. M. Koolhaas, and B. Buwalda (2009) Methotrexate decreases hippocampal cell proliferation

[16] Winocur, G., J. Vardy, M. A. Binns, L. Kerr, and I. Tannock (2006) The effects of the anticancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice.

[17] Verstappen, C. C., J. J. Heimans, k. Hoekman, and T. J. Postma (2003) Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal

[18] Ahles, T. A., A. J. Saykin, W. W. Noll, C. T. Furstenberg, S. Guerin, B. Cole, and L. A. Mott (2003) The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psycho-oncology

[19] Saarto, T., C. Blomqvist, C. Ehnholm, M. R. Taskinen, and I. Elomaa (1996) Effects of chemotherapy-induced castration on serum lipids and apoproteins in premenopausal women with node-positive breast cancer. J. Clin. Endocrinol. Metab. 81: 4453-4457. [20] Phillips, K. A., and J. Bernhard (2003) Adjuvant breast cancer treatment and cognitive function: current knowledge and research directions. J. Nat. Cancer Inst. 95: 190-197. [21] Koochmeshgi, J., S. M. Hosseini-Mazinani, S. Morteza Seifati, N. Hosein-Pur-Nobari, and L. Teimoori-Toolabi (2004) Apolipoprotein E genotype and age at menopause. Ann.

[22] Srivastava, R. A., N. Srivastava, M. Averna, R. C. Lin, K. S. Korach, D. B. Lubahn, and G. Schonfeld (1997) Estrogen up-regulates apolipoprotein E (ApoE) gene expression by

and induces memory deficits in rats. Behav. Brain Res. 201: 279-284.

recognition and spatial navigation in the elderly. Neuroscience 147: 6-17.

neuropathology. Acta. Neurol. Scand. Suppl. 185: 8-14.

survival in ovarian cancer. Cancer Res. 65: 331-337.

patients with cancer. Cancer Invest. 19: 812-820.



and raloxifene on serum lipids, apolipoprotein A1, apolipoprotein B and lipoprotein(a) in Greek postmenopausal women. Gynecol. Endocrinol. 18: 244-257.

[48] Francucci, C. M., P. Daniele, N. Iori, A. Camilletti, F. Massi, and M. Boscaro (2005) Effects of raloxifene on body fat distribution and lipid profile in healthy postmenopausal women. J. Endocrinol. Invest. 28: 623-631.

266 Lipoproteins – Role in Health and Diseases

395.

mammary carcinogenesis. Neoplasma 56: 124-129.

with breast cancer. Euro. J. Cancer 37: 1510-1513.

postmenopausal patients'. Ann. Oncol. 15: 211-217.

clinical traumatology practice. Open. Orthop. J. 3: 14-21.

cognition. J. Women's Health (Larchmt). 19: 371-379.

acquisition in male rats. Neurosci. Res. 58: 272-277.

N. Engl. J. Med. 344: 1207-1213.

Metabolism 55: 972-979.

5152.

[36] Sadlonova, V., P. Kubatka, K. Kajo, D. Ostatnikova, G. Nosalova, K. Adamicova, and J. Sadlonova (2009) Side effects of anastrozole in the experimental pre-menopausal

[37] Phillips, K. A., K. Ribi, Z. Sun, A. Stephens, A. Thompson, V. Harvey, B. Thurlimann, F. Cardoso, O. Pagani, A. S. Coates, A. Goldhirsch, K. N. Price, R. D. Gelber, and J. Bernhard (2010) Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. Breast 19: 388-

[38] Thurlimann, B., A. Keshaviah, A. S. Coates, H. Mouridsen, L. Mauriac, J. F. Forbes, R. Paridaens, M. Castiglione-Gertsch, R. D. Gelber, M. Rabaglio, I. Smith, A. Wardley, K. N. Price, and A. Goldhirsch (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353: 2747-2757. [39] Elisaf, M. S., E. T. Bairaktari, C. Nicolaides, B. Kakaidi, C. S. Tzallas, A. Katsaraki, and N. A. Pavlidis (2001) Effect of letrozole on the lipid profile in postmenopausal women

[40] Atalay, G., L. Dirix, L. Biganzoli, L. Beex, M. Nooij, D. Cameron, C. Lohrisch, T. Cufer, J. P. Lobelle, M. R. Mattiaci, M. Piccart, and R. Paridaens (2004) The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in

[41] Rey, J. R., E. V. Cervino, M. L. Rentero, E. C. Crespo, A. O. Alvaro, and M. Casillas (2009) Raloxifene: mechanism of action, effects on bone tissue, and applicability in

[42] Espeland, M. A., S. A. Shumaker, M. Limacher, S. R. Rapp, T. B. Bevers, D. H. Barad, L. H. Coker, S. A. Gaussoin, M. L. Stefanick, D. S. Lane, P. M. Maki, and S. M. Resnick (2010) Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on

[43] Yaffe, K., K. Krueger, S. Sarkar, D. Grady, E. Barrett-Connor, D. A. Cox, and T. Nickelsen (2001) Cognitive function in postmenopausal women treated with raloxifene.

[44] Alejandre-Gomez, M., L. M. Garcia-Segura, and I. Gonzalez-Burgos (2007) Administration of an inhibitor of estrogen biosynthesis facilitates working memory

[45] Legault, C., P. M. Maki, S. M. Resnick, L. Coker, P. Hogan, T. B. Bevers, and S. A. Shumaker (2009) Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene. J. Clin. Oncol. 27: 5144-

[46] Dayspring, T., Y. Qu, and C. Keech (2006) Effects of raloxifene on lipid and lipoprotein levels in postmenopausal osteoporotic women with and without hypertriglyceridemia.

[47] Christodoulakos, G. E., I. V. Lambrinoudaki, C. P. Panoulis, C. A. Papadias, E. E. Kouskouni, and G. C. Creatsas (2004) Effect of hormone replacement therapy, tibolone

